AML Hub Satellite Symposium highlights: How does MRD impact outcome of stem cell transplantation in AML – now and in the future?

At the 46th Annual Meeting of the European Society for Blood and Marrow...

AML Hub Satellite Symposium: Round table discussion and conclusions from the Chair

The virtual AML Hub Satellite Symposium at the 46th Annual Meeting of the European Society for Blood and Marrow...

Why should we use MRD assessment post hematopoietic stem cell transplantation?

Professor Charles Craddock, University of Birmingham, Birmingham, UK, presented the topic ‘Why should we use MRD...

Does current evidence support the use of MRD-guided treatment before transplant in patients with AML?

Professor Adriano Venditti, University of Rome Tor Vergata, Rome, IT, presented the topic ‘Does...

Beat AML Master trial: can we use precision medicine to treat older patients with AML?

The Beat AML Master trial is an umbrella study which contains 11 sub-studies covering the most prominent subtypes...

Gemtuzumab ozogamicin for salvage CBF-AML: A case report

During the 2nd How to Diagnose and Treat Acute Leukaemia conference organized by the European School of Haematology (ESH), there was an...

APR-246 plus azacitidine for patients with TP53 mutated MDS and AML

The GFM-APR trial is investigating the safety and efficacy of APR-246 plus AZA as maintenance therapy for patients with TP53 mutant...

Magrolimab plus azacytidine in patients with myelodysplastic syndromes and acute myeloid leukemia

During the American Society of Clinical Oncology (ASCO) Virtual Meeting 2020, David Sallman from the...

TP53 mutations linked to increased immune infiltration and IFN-γ signaling in patients with AML

Patients with acute myeloid leukemia (AML) are considered to be in the high cytogenetic risk category if...

TP53 mutations in the determination of azacitidine response for older patients with AML

Optimal treatment strategies for older patients with acute myeloid leukemia (AML) are elusive and the overall...

Eprenetapopt receives FDA Fast Track designation for the treatment of AML

On November 30, 2020, it was announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to...

ASH 2019 round up – Magrolimab

During the American Society of Hematology (ASH) annual meeting in 2019, a phase Ib study (NCT03248479) of magrolimab in combination with azacitidine was featured by the...